Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Minority Interest (2016 - 2017)

Rein Therapeutics (RNTX) has disclosed Minority Interest for 2 consecutive years, with $130.4 million as the latest value for Q2 2017.

  • On a quarterly basis, Minority Interest changed N/A to $130.4 million in Q2 2017 year-over-year; TTM through Jun 2017 was $130.4 million, a N/A change, with the full-year FY2016 number at $129.7 million, up 32.83% from a year prior.
  • Minority Interest was $130.4 million for Q2 2017 at Rein Therapeutics, up from $129.7 million in the prior quarter.
  • In the past five years, Minority Interest ranged from a high of $130.4 million in Q2 2017 to a low of $129.7 million in Q4 2016.